Teva
NYSE:TEVAPharmaPetah Tikva, Israel, Israel · Est. 1901 · 43,000 employees
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines.
6
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
14
Indications↗
Distinct diseases across all programs
426
Clinical Trials↗
All sponsored trials (all statuses)
86
Orange Book Patents
Across 6 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
6 drugs in development
Approved1
Phase 33
Phase 24
Phase 12
Preclinical1
By Therapeutic Area
top 6
Respiratory
431%
Immunology
215%
Metabolic & Endocrine
18%
Gastroenterology
18%
Neurology
18%
Dermatology
18%
R&D Momentum
44/100
Pipeline Velocity
11/100
Trial Completion Rate
88/100
Pipeline Concentration
16/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 7, 2026
Active, not recruiting
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma
Jul 7, 2026
Recruiting
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Jul 2, 2026
Active, not recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Jul 1, 2026
Completed
A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients With Schizophrenia
Earlier
Jun 26, 2026TrialA 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination Compared to Fluticasone Propionate, Albuterol Sulfate or Placebo Delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older With Asthma
Jun 24, 2026TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age
Mar 11, 2026TrialHARMONY: Fremanezumab Preventive in Episodic Migraine
Apr 15, 2025TrialFOCUS: Fremanezumab in Episodic Migraine
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$15.6B
Revenue
—
Cash
CEOKåre Schultz
Founded1901
Employees43,000
HQPetah Tikva, Israel, Israel
ExchangeNYSE:TEVA
Websitetevapharm.com
LinkedInCompany Page
Therapeutic Focus
NeurologyOncologyHematologyImmunologyRespiratoryInfectious DiseaseOtherMusculoskeletalPsychiatryCardiovascularGastroenterologyDermatologyOphthalmologyMetabolic & EndocrineRare DiseaseNephrology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Gastroenterology
Neurology
Cardiovascular
Gastroenterology
Celiac Disease
TEV-53408Phase 2
Immunology
Allergic Asthma
ProventilPhase 1
Ulcerative Colitis
TEV-48574Phase 2
Neurology
Respiratory
Lung Disease
ProventilPhase 1
Status Asthmaticus
ProventilPhase 1
Showing 15 of 17 programs
Regulatory
Regulatory Timeline
20021 event
FDAAug 9
Eloxatin — ELOXATIN
Application NDA021492 (NDA)
20052 events
FDAJan 31
Eloxatin — ELOXATIN
Application NDA021759 (NDA)
FDAJan 7
Taxol — ABRAXANE
Application NDA021660 (NDA)
20063 events
FDAMay 16
Azilect — AZILECT
Application NDA021641 (NDA)
FDAApr 13
ReVia — VIVITROL
Application NDA021897 (NDA)
FDAJan 27
Aerobid — AEROSPAN HFA
Application NDA021247 (NDA)
20092 events
FDANov 5
Istodax — ISTODAX
Application NDA022393 (NDA)
FDAAug 7
Eloxatin — OXALIPLATIN
Application NDA022160 (NDA)
20121 event
FDAOct 26
Synribo — SYNRIBO
Application NDA203585 (NDA)
20132 events
FDAOct 25
Zohydro Er — ZOHYDRO ER
Application NDA202880 (NDA)
FDAMar 27
Tecfidera — TECFIDERA
Application NDA204063 (NDA)
20141 event
FDANov 20
Zohydro Er — HYSINGLA ER
Application NDA206627 (NDA)
20161 event
FDAMar 23
Cinqair — CINQAIR
Application BLA761033 (BLA)
20172 events
FDAApr 3
Austedo — AUSTEDO
Application NDA208082 (NDA)
FDAJan 17
Zohydro Er — VANTRELA ER
Application NDA207975 (NDA)
20181 event
FDASep 14
Ajovy — AJOVY
Application BLA761089 (BLA)
20201 event
FDAMar 13
Istodax — ROMIDEPSIN
Application NDA208574 (NDA)
20221 event
FDAJul 27
Taxol — PACLITAXEL
Application NDA211875 (NDA)
20232 events
FDAMay 11
Taxol — PACLITAXEL
Application NDA216338 (NDA)
FDAFeb 17
Austedo — AUSTEDO XR
Application NDA216354 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)